Antigen Express, the Worcester-based subsidiary of Toronto’s Generex Biotechnology Corp., says a Phase II clinical trial of its cancer vaccine has produced positive results.
The company presented the results at a summit at Cambridge Healthtech Institute. Generex said the relapse rate at 17 months for breast cancer patients treated with the vaccine was half that of patients in a control group.
The company said it’s also finished a Phase I trial in prostate cancer patients. It said all its trials so far have had positive results.
